BUSCADOR RECOLECTA

Supplementary Table 1. Cardiac function assessed through echocardiography of patients included in the study. Supplementary Table 2. Adjusted means of metabolic phenotypes of fatty liver disease with visceral adipose tissue and visceral adipose tissue/subcutaneous adipose tissue ratio. Supplementary Table 3. Associations between metabolic phenotypes of fatty liver disease and high indexed epicardial adipose tissue (>68.1 mL). Supplementary Table 4. Associations between metabolic phenotypes of fatty liver disease and moderate to severe coronary artery calcification (Agatston CAC score>100)., [Background] To better understand the patient's heterogeneity in fatty liver disease (FLD), metabolic dysfunction–associated fatty liver disease (MAFLD) was proposed by international experts as a new nomenclature for nonalcoholic fatty liver disease (NAFLD). We aimed to evaluate the cardiovascular risk, assessed through coronary artery calcium (CAC) and epicardial adipose tissue (EAT), of patients without FLD and patients with FLD and its different subtypes., [Methods] Cross sectional study of 370 patients. Patients with FLD were divided into 4 groups: FLD without metabolic dysfunction (non-MD FLD), MAFLD and the presence of overweight/obesity (MAFLD-OW), MAFLD and the presence of two metabolic abnormalities (MAFLD-MD) and MAFLD and the presence of T2D (MAFLD-T2D). MAFLD-OW included two subgroups: metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUHO). The patients without FLD were divided into 2 groups: patients without FLD and without MD (non-FLD nor MD; reference group) and patients without FLD but with MD (non-FLD with MD). EAT and CAC (measured through the Agatston Score) were determined by computed tomography., [Results] Compared with the reference group (non-FLD nor MD), regarding EAT, patients with MAFLD-T2D and MAFLD-MUHO had the highest risk for CVD (OR 15.87, 95% CI 4.26-59.12 and OR 17.60, 95% CI 6.71-46.20, respectively), patients with MAFLD-MHO were also at risk for CVD (OR 3.62, 95% CI 1.83-7.16), and patients with non-MD FLD did not have a significantly increased risk (OR 1.77; 95% CI 0.67-4.73). Regarding CAC, patients with MAFLD-T2D had an increased risk for CVD (OR 6.56, 95% CI 2.18-19.76). Patients with MAFLD-MUHO, MAFLD-MHO and non-MD FLD did not have a significantly increased risk compared with the reference group (OR 2.54, 95% CI 0.90-7.13; OR 1.84, 95% CI 0.67-5.00 and OR 2.11, 95% CI 0.46-9.74, respectively)., [Conclusion] MAFLD–T2D and MAFLD–OW phenotypes had a significant risk for CVD. MAFLD new criteria reinforced the importance of identifying metabolic phenotypes in populations as it may help to identify patients with higher CVD risk and offer a personalized therapeutic management in a primary prevention setting., Peer reviewed

[EN] It contains a netCDF file which needs specific data analysis software. [ES] Contiene un fichero netCDF que necesita software de análisis de datos específico., [ES] El dataset SEDIDatabase se actualiza periódicamente, se puede consultar y descargar en el siguiente enlace: https://sedi.csic.es/ [EN] The SEDIDatabase dataset is updated periodically, it can be consulted and downloaded at the following link: https://sedi.csic.es/, [EN] This dataset includes series of the Standardized Evapotranspiration Deficit at 0.25º spatial resolution and monthly time resolution at global scale from 1980., [ES] Esta base de datos proporciona el Standardized Evapotranspiration Deficit Index a escala global con una resolución espacial de 0.25 grados y una resolución temporal mensual desde 1980., This work was supported by the research projects PCIN-2015-220 and CGL2014-52135-C03-01 financed by the Spanish Commission of Science and Technology and FEDER. IMDROFLOOD financed by the Water Works 2014 co-funded all of the European Commission and INDECIS, which is part of ERA4CS, an ERA-NET initiated by JPI Climate, and funded by FORMAS(Sweden), DLR(Germany),BMWFW(Austria), IFD (Denmark), MINECO (Spain), and ANR (France), with co-funding by the European Union (Grant 690462)., Peer reviewed

Supplemental Table 1. Fatty acid composition in spleen cells of wild-type C57BL/6J mice at the end of 20-week dietary regimens. Supplemental Figure 1. An example of the gating strategy used to identify CD4+ (CD45+CD3+CD4+CD8–) and CD8+ (CD45+CD3+CD4–CD8+) T cells in spleen or bone marrow of wild-type C57BL/6J mice fed with the LFD and HFDs at the end of 20-week dietary regimens. SSC-A side scatter area, FSC-A forward scatter area, CD cluster of differentiation. Supplemental Figure 2. An example of the gating strategy used to identify CD3+ T cells and CD4+ and CD8+ T cell subsets in spleen cell suspensions of lean wild-type C57BL/6J mice after fatty acid treatment for 18 h. A similar gating strategy was used for bone marrow cell suspensions. SSC-A side scatter area, FSC-A forward scatter area, CD cluster of differentiation, 7-AAD 7-amino-actinomycin D. Supplemental Figure 3. CD3+ and CD4+ T cells in spleen cell suspensions of lean wild-type C57BL/6J mice treated with palmitic acid or oleic acid at indicated concentrations. The percentage relative to the negative control (cells without any treatment) of CD3+ and CD4+ T cells after the treatment of spleen cell suspensions with low-endotoxin fatty acid-free BSA control, BSA-palmitic acid complex (25-300 M) (A, D) or BSA-oleic acid complex (25-300 M) (B, E) for 18 h. The comparative of palmitic and oleic acids at 300 M is also shown (C, F). The data are presented as the mean (bars) and individual points ± SD values (n = 6), and those marked with different letters are significantly different (p<0.05). Differences between groups were assessed by one-way ANOVA with Tukey’s post hoc test or, in the case of variance heterogeneity, by Kruskal-Wallis with Bonferroni correction. CD cluster of differentiation, PA palmitic acid, OA oleic acid. Supplemental Figure 4. CD8+ T cells in spleen and CD3+ T cells in bone marrow (BM) cell suspensions of lean wild-type C57BL/6J mice treated with palmitic acid or oleic acid at indicated concentrations. The percentage relative to the negative control (cells without any treatment) of CD8+ T cells (spleen) and CD3+ T cells (BM) after the treatment of each cell suspension with low-endotoxin fatty acid-free BSA control, BSA-palmitic acid complex (25-300 M) (A, D) or BSA-oleic acid complex (25-300 M) (B, E) for 18 h. The comparative of palmitic and oleic acids at 300 M is also shown (C, F). The data are presented as the mean (bars) and individual points ± SD values (n = 6), and those marked with different letters are significantly different (p<0.05). Differences between groups were assessed by one-way ANOVA with Tukey’s post hoc test or, in the case of variance heterogeneity, by Kruskal-Wallis with Bonferroni correction. CD cluster of differentiation, PA palmitic acid, OA oleic acid. Supplemental Figure 5. CD4+ and CD8+ T cells in bone marrow (BM) cell suspensions of lean wild-type C57BL/6J mice treated with palmitic acid or oleic acid at indicated concentrations. The percentage relative to the negative control (cells without any treatment) of CD4+ and CD8+ T cells after the treatment of BM cell suspensions with low-endotoxin fatty acid-free BSA control, BSA-palmitic acid complex (300 M) (A, D) or BSA-oleic acid complex (300 M) (B, E) for 18 h. The comparative of palmitic and oleic acids at 300 M is also shown (C, F). The data are presented as the mean (bars) and individual points ± SD values (n = 6), and those marked with different letters are significantly different (p<0.05). Differences between groups were assessed by one-way ANOVA with Tukey’s post hoc test or, in the case of variance heterogeneity, by Kruskal-Wallis with Bonferroni correction. CD cluster of differentiation, PA palmitic acid, OA oleic acid., Peer reviewed

Supplementary Movie S1. FRAPexperiment in which the quick recovery of mEGFP-JMJD3 puncta after photobleaching is observed. Supplementary Movie S2. FRAP experiment in which the aggregation of mEGFP-JMJD3 is appreciated by means of a reduced mobility after photobleaching. Supplementary Data file 1. Table depicting the parameters that assess the quality of the Chst8 4C-seq experiments for each sample as previously described. Briefly, the % of reads containing VP sequence should be above 90, the % of fragments that map in cis above 50, and the % of reads that map in unique sites within 1Mb around VP above 60. Supplementary Data file 2 and 3. Tables containing the quality measurements for each sample of the Ldlrad4 4C-seq (2) and Aopep 4C-seq (3) experiments, according to the parameters previously described. Briefly, the % of reads containing VP sequence should be above 90, the % of fragments that map in cis above 50, and the % of reads that map in unique sites within 1Mb around VP above 60., Peer reviewed

A, Predictive models for hospital discharge during the first week in mild patients. B, Predictive models for worsening of clinical status during the first week in patients who were admitted mildly ill. AUC, area under the curve., Peer reviewed

S2 Fig. Migration and activation marker expressing in monocytes subset in mild and several/critical patients (S/C)., Peer reviewed

Quantitative variables are expressing as number (percentage) or median (interquartile range). Pa value for differences between patients who were or not discharged. Pb value for differences between patients who who did and did not get wore. SpO2, peripheral capillary oxygen saturation; CRP, C-reactive protein; LDH, Lactate dehydrogenase; NLR, neutrophil/lymphocyte ratio., Peer reviewed

AUC, area under the curve; SE, sensitivity; S, specificity; PPV, positive predictive value; NPV, negative predictive value. SpO2, peripheral capillary oxygen saturation; CRP, C-reactive protein; LDH, Lactate dehydrogenase; NLR, neutrophil/lymphocyte ratio; TNF-α; tumor necrosis factor α; IL-6, interleukine-6; IL-8, interleukine-8; IL-1β, interleukine-1β; MIP-1β, macrophage inflammatory proteins 1β; sCD25, soluble receptor interleukine-2; IP-10, interferon γ-induced protein 10., Peer reviewed

AUC, area under the curve; SE, sensitivity; S, specificity; PPV, positive predictive value; NPV, negative predictive value. SpO2, peripheral capillary oxygen saturation; CRP, C-reactive protein; LDH, Lactate dehydrogenase; NLR, neutrophil/lymphocyte ratio; TNF-α; tumor necrosis factor α; IL-6, interleukine-6; IL-8, interleukine-8; IL-1β, interleukine-1β; MIP-1β, macrophage inflammatory proteins 1β; sCD25, soluble receptor interleukine-2; IP-10, interferon γ-induced protein 10., Peer reviewed

Data are expressed by percentage and interquartile range. Medians fluorescence intensitive (MFI) were calculated in those markets that have a high rate of expression., Peer reviewed